Sanofi ADR Congressional Trading
According to U.S. congressional financial disclosures filed under the STOCK Act, members of Congress have reported 44 trades in Sanofi ADR (NASDAQ: SNY) since 2014, across 20 members, worth an estimated $980.02K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts). 18 buys against 26 sells, a modestly sell-led skew, with Democratic members responsible for 30% of the trades and Republican members 70%. The most recent disclosure shown was filed July 2026, and Lisa McClain has filed the most SNY transactions among those shown, with 2. Other recent filers include Alan Armstrong and Rohit Khanna. One notable disclosed move was a sale by Rohit Khanna on November 14, 2025, down 6.8% since. These figures are drawn from public House and Senate periodic transaction reports and reflect what members were required to disclose, not the current market value of any position. Sanofi ADR's current Quantellect Tide Score is 72 out of 100 (High Tide), Top 15% of universe (3876); the Tide Score is generated algorithmically from public filings and market data and is not investment advice. For the full record, including the month-by-month buy and sell timeline, the party breakdown, top buyers and sellers, and every individual filing, see the Sanofi ADR (SNY) stock overview and the complete trade table below.
Data updated
Price & congressional trade timeline
Party breakdown
Sanofi ADR congressional trading activity
| Politician | Published | Traded | Filed After | Type | Size | Return | Owner | |
|---|---|---|---|---|---|---|---|---|
 Alan Armstrong Senate | Jul 21, 2026 | Mar 30, 2026 | 113 days | BUY |  $15,001 - $50,000 | +3.97% | Self | |
 Rohit Khanna House | Dec 8, 2025 | Nov 14, 2025 | 24 days | SELL | $15,001 - $50,000 | -6.84% | Spouse | |
 Lisa McClain House | Oct 23, 2025 | Sep 11, 2025 | 42 days | SELL | $1,001 - $15,000 | +1.94% | Spouse | |
Lisa McClain House | Oct 22, 2025 | Sep 11, 2025 | 41 days | SELL | $1,001 - $15,000 | +1.94% | Spouse |
Sanofi ADR (SNY) congressional trading FAQ
Can members of Congress legally trade Sanofi ADR (SNY) stock?
Yes. Members of Congress are permitted to trade individual stocks, including Sanofi ADR (SNY), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; it does not imply any trade was improper.
Are congressional Sanofi ADR (SNY) trades public?
Yes. Every congressional trade in Sanofi ADR (SNY) on this page comes from mandatory public STOCK Act disclosure filings, which are filed with a delay and may be revised.
How many times has Congress traded Sanofi ADR (SNY)?
Members of Congress have disclosed 44 trades in Sanofi ADR (SNY) worth $980.02K across 20 members, according to public STOCK Act filings.
Which members of Congress have traded Sanofi ADR (SNY)?
Recent and active filers of Sanofi ADR (SNY) disclosures include Lisa McClain, Alan Armstrong, Rohit Khanna. The full member-by-member trade list is on this page.
Do Democrats or Republicans trade Sanofi ADR (SNY) more?
Across disclosed Sanofi ADR (SNY) trades, 30% were by Democrats and 70% by Republicans, led by Republicans (70%).
What is the most recent congressional Sanofi ADR (SNY) trade?
The most recent disclosed Sanofi ADR (SNY) trade was a purchase by Alan Armstrong, filed Jul 20, 2026.
What is Sanofi ADR (SNY)'s Tide Score?
Sanofi ADR (SNY) has a Quantellect Tide Score of 72 (High Tide). The Tide Score is a 0-100 read blending price forecast, smart-money flow, technicals, and social sentiment; higher is more bullish.
Browse all stocks Congress tradesCongressional trading overviewSanofi ADR (SNY) stock overview
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. The Tide Score and other figures are generated algorithmically from public filings and market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.